Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.49 |
| ▸ | CTSG | P08311 | 7/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 7/20 | 0.49 |
| ▸ | CMA1 | P23946 | 7/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493020 | 0.84 | GAA (0.55) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL27453160 | 0.81 | MAPT (0.54) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL2486914 | 0.80 | SMN1; SMN2 (0.51) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL28458590 | 0.79 | SLC1A2 (0.51) | CTRB1GAAALDH1A1MEN1KMT2A | |
| SCHEMBL24834183 | 0.77 | MAPT (0.50) | PRSS1CTSGCTRB1CMA1POLB | |
| SCHEMBL3486823 | 0.77 | NPC1 (0.45) | PRSS1CTSGCTRB1CMA1POLB | |
| SCHEMBL27556148 | 0.75 | PRSS1 (0.56) | PRSS1CTSGCTRB1CMA1AAK1 | |
| SCHEMBL2319522 | 0.75 | PRSS1 (0.47) | PRSS1CTSGCTRB1CMA1AAK1 | |
| SCHEMBL9459921 | 0.75 | GAA (0.59) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL9334912 | 0.75 | DGAT1 (0.34) | GAAMEN1KMT2ALMNACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376502-B1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| CN-102388054-B | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2015-03-04 | — | — | CN | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| CN-102388054-A | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2012-03-21 | — | — | CN | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| EP-2376502-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | PRSS1 1476/4885CTSG 1819/4885CTRB1 1930/4885 |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | PRSS1 1476/4885CTSG 1819/4885CTRB1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.